Richard Schilsky to Drug Evaluation
This is a "connection" page, showing publications Richard Schilsky has written about Drug Evaluation.
Connection Strength
0.296
-
Drug safety and drug efficacy: two sides of the same coin. Clin Cancer Res. 2007 May 01; 13(9):2533-4.
Score: 0.074
-
Antifolates: the next generation. Semin Oncol. 1992 Dec; 19(6):707-19.
Score: 0.027
-
Phase II study of echinomycin in patients with advanced breast cancer: a report of Cancer and Leukemia Group B protocol 8641. Invest New Drugs. 1991 Aug; 9(3):269-72.
Score: 0.025
-
A phase I study of cisplatin, 5-fluorouracil and leucovorin with escalating doses of hydroxyurea in chemotherapy naive patients. Eur J Cancer. 1991; 27(2):217-8.
Score: 0.024
-
Five-day infusion of fluorodeoxyuridine with high-dose oral leucovorin: a phase I study. Cancer Chemother Pharmacol. 1991; 28(1):69-73.
Score: 0.024
-
Sequential hydroxyurea-cytarabine chemotherapy for refractory non-Hodgkin's lymphoma. J Clin Oncol. 1987 Mar; 5(3):419-25.
Score: 0.018
-
Phase I clinical and pharmacological study of thymidine (NSC 21548) and cis-diamminedichloroplatinum(II) in patients with advanced cancer. Cancer Res. 1986 Aug; 46(8):4184-8.
Score: 0.017
-
Cytarabine-cis-platin interactions in patients with advanced cancer. Semin Oncol. 1985 Jun; 12(2 Suppl 3):171-6.
Score: 0.016
-
Phase I clinical evaluation of cytarabine and cisplatin in patients with advanced cancer. Cancer Treat Rep. 1984 Sep; 68(9):1097-102.
Score: 0.015
-
Phase I trial and pharmacokinetics of aziridinylbenzoquinone (NSC 182986) in humans. Cancer Res. 1982 Apr; 42(4):1582-6.
Score: 0.013
-
Cytosine arabinoside and cisplatin for advanced breast cancer. A phase II study of the Cancer and Leukemia Group B. Cancer. 1991 Oct 15; 68(8):1696-8.
Score: 0.006
-
Clinical cardiotoxicity of esorubicin (4'-deoxydoxorubicin,DxDx): prospective studies with serial gated heart scans and reports of selected cases. A Cancer and Leukemia Group B report. Invest New Drugs. 1990 May; 8(2):221-6.
Score: 0.006
-
Platinum-based combination chemotherapy in advanced non-small cell lung cancer: a randomized phase II trial of the Cancer and Leukemia Group B. Med Pediatr Oncol. 1990; 18(3):197-202.
Score: 0.006
-
Hydroxyurea, fluorouracil, and concomitant radiotherapy in poor-prognosis head and neck cancer: a phase I-II study. J Clin Oncol. 1989 Jun; 7(6):761-8.
Score: 0.005
-
Cisplatin, 5-fluorouracil, and high-dose oral leucovorin for advanced head and neck cancer. Cancer. 1989 Mar 15; 63(6 Suppl):1048-53.
Score: 0.005
-
Hydroxyurea and etoposide: in vitro synergy and phase I clinical trial. J Natl Cancer Inst. 1988 Nov 02; 80(17):1412-6.
Score: 0.005
-
Limited sampling models for amonafide (NSC 308847) pharmacokinetics. Cancer Res. 1988 Jul 15; 48(14):4127-30.
Score: 0.005
-
Phase I clinical and pharmacological study of 72-hour continuous infusion of etoposide in patients with advanced cancer. Cancer Res. 1987 Apr 01; 47(7):1952-6.
Score: 0.005